CEO Research Orientation, Corporate Context and Firm Innovation in the Biopharmaceutical Industry

Nino van de Wal; Christophe Boone; Victor Gilsing; Bob Walrave

doi:10.5465/AMBPP.2017.10883abstract

CEO Research Orientation, Corporate Context and Firm Innovation in the Biopharmaceutical Industry

Nino van de Wal, Christophe Boone, Victor Gilsing, Bob Walrave

Innovation Technology Entrepreneurship & Marketing

Research output: Contribution to conference › Abstract › Academic

Abstract

This study develops and tests an integrative framework that explains when and why CEOs influence firm-level innovation. Empirical evidence from 109 CEOs of 87 U.S. based biopharmaceutical firms over the period 2001-2013 reveals that research orientated CEOs–those with an ability and motivation for science and technology–increase their firm’s innovation outcomes. The results indicate that the CEO-innovation relationship strongly depends on the extent of CEO discretion, which is shaped by the corporate context. A more detailed analysis shows that research oriented CEOs influence innovation through a R&D intensive strategy. These insights contribute to a more comprehensive understanding of CEO strategic choices and processes that result in firm-level innovation, and build a better understanding of why firms differ in their innovation performance

Original language	English
Number of pages	1
DOIs	https://doi.org/10.5465/AMBPP.2017.10883abstract
Publication status	Published - 2017
Event	77th Annual Meeting of the Academy of Management, AOM 2017 - Atlanta, United States Duration: 4 Aug 2017 → 8 Aug 2017 Conference number: 77 http://aom.org/meetings/aom2017.html

Conference

Conference	77th Annual Meeting of the Academy of Management, AOM 2017
Abbreviated title	AOM 2017
Country/Territory	United States
City	Atlanta
Period	4/08/17 → 8/08/17
Internet address	http://aom.org/meetings/aom2017.html

Access to Document

10.5465/AMBPP.2017.10883abstract

Cite this

@conference{7ab17fd3ead048e8995f43341a3af908,

title = "CEO Research Orientation, Corporate Context and Firm Innovation in the Biopharmaceutical Industry",

abstract = "This study develops and tests an integrative framework that explains when and why CEOs influence firm-level innovation. Empirical evidence from 109 CEOs of 87 U.S. based biopharmaceutical firms over the period 2001-2013 reveals that research orientated CEOs–those with an ability and motivation for science and technology–increase their firm{\textquoteright}s innovation outcomes. The results indicate that the CEO-innovation relationship strongly depends on the extent of CEO discretion, which is shaped by the corporate context. A more detailed analysis shows that research oriented CEOs influence innovation through a R&D intensive strategy. These insights contribute to a more comprehensive understanding of CEO strategic choices and processes that result in firm-level innovation, and build a better understanding of why firms differ in their innovation performance",

author = "{van de Wal}, Nino and Christophe Boone and Victor Gilsing and Bob Walrave",

year = "2017",

doi = "10.5465/AMBPP.2017.10883abstract",

language = "English",

note = "77th Annual Meeting of the Academy of Management, AOM 2017, AOM 2017 ; Conference date: 04-08-2017 Through 08-08-2017",

url = "http://aom.org/meetings/aom2017.html",

}

TY - CONF

T1 - CEO Research Orientation, Corporate Context and Firm Innovation in the Biopharmaceutical Industry

AU - van de Wal, Nino

AU - Boone, Christophe

AU - Gilsing, Victor

AU - Walrave, Bob

N1 - Conference code: 77

PY - 2017

Y1 - 2017

N2 - This study develops and tests an integrative framework that explains when and why CEOs influence firm-level innovation. Empirical evidence from 109 CEOs of 87 U.S. based biopharmaceutical firms over the period 2001-2013 reveals that research orientated CEOs–those with an ability and motivation for science and technology–increase their firm’s innovation outcomes. The results indicate that the CEO-innovation relationship strongly depends on the extent of CEO discretion, which is shaped by the corporate context. A more detailed analysis shows that research oriented CEOs influence innovation through a R&D intensive strategy. These insights contribute to a more comprehensive understanding of CEO strategic choices and processes that result in firm-level innovation, and build a better understanding of why firms differ in their innovation performance

AB - This study develops and tests an integrative framework that explains when and why CEOs influence firm-level innovation. Empirical evidence from 109 CEOs of 87 U.S. based biopharmaceutical firms over the period 2001-2013 reveals that research orientated CEOs–those with an ability and motivation for science and technology–increase their firm’s innovation outcomes. The results indicate that the CEO-innovation relationship strongly depends on the extent of CEO discretion, which is shaped by the corporate context. A more detailed analysis shows that research oriented CEOs influence innovation through a R&D intensive strategy. These insights contribute to a more comprehensive understanding of CEO strategic choices and processes that result in firm-level innovation, and build a better understanding of why firms differ in their innovation performance

U2 - 10.5465/AMBPP.2017.10883abstract

DO - 10.5465/AMBPP.2017.10883abstract

M3 - Abstract

T2 - 77th Annual Meeting of the Academy of Management, AOM 2017

Y2 - 4 August 2017 through 8 August 2017

ER -

CEO Research Orientation, Corporate Context and Firm Innovation in the Biopharmaceutical Industry

Abstract

Conference

Access to Document

Fingerprint

Cite this